Clinical trials: Smoking
Smoking, Smoking Behaviors
CSD210202: A Study to Assess Nicotine Uptake From Electronic Nicotine Delivery Systems
This is an open-label, randomized, 5-way crossover study designed to evaluate plasma nicotine pharmacokinetic (PK) parameters following an ad libitum use of Electronic Nicotine Delivery System (ENDS) investigational products…
- Conditions
- Smoking, Smoking Behaviors, Tobacco Use, Tobacco Smoking
- Trial name
- NCT04751461
- Testing
- Product A, Product B, Product C
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Smoking Cessation
Smoking Reduction or Cessation With Nicotine Replacement Therapy
The purpose of this study is to test the success rate of smoking reduction or cessation with different nicotine products.
- Trial name
- NCT00840242
- Testing
- Nicotine gum, Nicotine inhaler
- Where
- 2 sites in Czechia
- Volunteers
- 314 people
- Sponsor
- McNeil AB
Cannabis Abuse
Drug-Drug Interaction Between THC and AEF0117
This trial is a single center, double blind, placebo-controlled trial in healthy male and female recreational cannabis users with placebo and AEF0117 dosed in a fixed sequence.
- Trial name
- DDI (NCT06395688)
- Testing
- 3ß-(4-methoxybenzyloxy)pregn-5-en-20-one
- Volunteers
- healthy volunteers welcome
- Sponsor
- Aelis Farma
Smoking, Tobacco
Nicotine Pharmacokinetics of THS Single Use of a Regular or a Menthol Stick Compared to CIG
The purpose of this study was to describe the nicotine pharmacokinetic (PK) profile during and after single use of THS (Induction heating technology, with either a regular or menthol stick) compared to singular CIG smoking in…
- Trial name
- NCT05789420
- Testing
- P1R stick, P1M stick, CIG
- Where
- United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Obesity, Smoking
Africa and Middle East Cardiovascular Epidemiological Study
This is a cross-sectional, epidemiological study to determine the prevalence of cardiovascular risk factors such as obesity, smoking, dyslipidemia, diabetes mellitus and hypertension in patients attending General Practice clinics…
- Conditions
- Obesity, Smoking, Dyslipidemia, Diabetes Mellitus
- Trial name
- ACE (NCT01243138)
- Where
- 73 sites in Algeria, Cameroon and 12 more
- Volunteers
- 4,386 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Smoking Behaviors, Smoking ( Cigarette)
A Study to Assess Nicotine Uptake From a Menthol Electronic Nicotine Delivery System Product
This will be a randomized, open-label, 2-way crossover, single-site study designed to evaluate elements of abuse liability (AL), including subjective effects and physiological measures (pharmacodynamics [PD]), and plasma nicotine…
- Conditions
- Smoking Behaviors, Smoking ( Cigarette), Tobacco Use, Abuse Liability
- Trial name
- NCT07881848
- Testing
- Menthol 5%, Combustible cigarette
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Vaping, E Cig Use
A Hybrid Program to Prevent Substance Use Risk Among Upper Elementary School Students Using a Positive Youth Development Approach
The goal of this randomized controlled trial is to evaluate a psychosocial school-based hybrid intervention which includes traditional classroom sessions and online e-learning modules to reduce risk of vaping and prescription…
- Conditions
- Vaping, E Cig Use, Prescription Drug Misuse
- Trial name
- NCT07162155
- Testing
- School-based Hybrid Intervention to Prevent Vaping and Prescription Drug Misuse
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Christopher Williams
Tobacco Use
Study to Evaluate Changes in Smokers Using on!® Nicotine Pouches
The purpose of this study is to generate evidence regarding the extent of reduction in exposure to selected HPHCs in adult smokers switching to on!® NPs.
- Trial name
- NCT05664672
- Testing
- OTDN Product 1, OTDN Product 2, OTDN Product 3
- Where
- 3 sites in United States
- Volunteers
- 149 people, healthy volunteers welcome
- Sponsor
- Altria Client Services LLC
Smoking
Exploratory THS 2.1 Biomarkers of Exposure Study
The goal of this exploratory study is to evaluate the effect of a candidate modified risk tobacco product (MRTP), THS 2.1, on selected biomarkers of exposure to harmful and potentially harmful smoke constituents (HPHCs), compared…
- Trial name
- ZRHX-EX-01 (NCT01780714)
- Testing
- Conventional cigarettes (CC), THS 2.1
- Where
- Poland
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Smoking Cessation
A Single Dose Study Investigating the Absorption and Elimination as Well as the Tolerability of Varenicline Transdermal Delivery System (e.g., a Patch) as Compared to Oral Varenicline in Adult Smokers.
1. To evaluate the absorption and elimination of varenicline Formulation A transdermal delivery system [TDS (patch)] compared to varenicline immediate release tablet (CHANTIX®). 2.
- Trial name
- NCT00661765
- Testing
- varenicline tartrate, varenicline free base
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Smoking Cessation
A Pilot Study Of Smoking Cessation Treatment Including Varenicline In Patients Scheduled For Planned Surgery
It is possible to offer smoking cessation treatment including varenicline to patients scheduled for elective surgery. This study will evaluate whether or not this will enable some patients to quit smoking for up to 4 weeks prior…
- Trial name
- NCT00889720
- Testing
- Varenicline
- Where
- 2 sites in France, Italy
- Volunteers
- 16 people
- Sponsor
- Pfizer
Smoking Cessation, Tobacco Use Cessation
Safety and Effectiveness of NicVAX in Treating Nicotine Dependent Individuals
Nicotine is highly addictive and many individuals are unable to quit smoking even with treatment. The purpose of this study is to determine the effectiveness of various doses of NicVAX in treating nicotine dependent individuals.
- Trial name
- NCT00218413
- Testing
- NicVAX
- Where
- Netherlands
- Volunteers
- 51 people
- Sponsor
- Nabi Biopharmaceuticals
Smoking
A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2
The objective of the ZRHR-ERS-09-EXT-US study is to further assess the effect of the Tobacco Heating System 2.2 (THS 2.2), a candidate Modified Risk Tobacco Product, compared to conventional cigarettes (CC) on the components of…
- Trial name
- NCT02649556
- Testing
- THS 2.2, CC
- Where
- 19 sites in United States
- Volunteers
- 672 people, healthy volunteers welcome
- Sponsor
- Philip Morris Products S.A.
Healthy
Trandolapril 4 mg Tablet Under Fasting Conditions
The objective of this study is to compare the rate and extent of absorption of trandolapril from a test formulation of Trandolapril 4 mg Tablets versus the reference Mavik® 4 mg Tablets under fasting conditions.
- Trial name
- NCT00840632
- Testing
- Trandolapril 4 mg Tablets, Mavik® 4 mg Tablets
- Where
- Canada
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Chronic Obstructive Pulmonary Disease (COPD)
The Use of a Forecasting System for Predicting Exacerbations of COPD
People with Chronic Obstructive Pulmonary Disease (COPD) often have periods during the year when their symptoms become worse. These are often due to an infection and are called "exacerbations" by doctors.
- Trial name
- NCT00788645
- Testing
- COPD self care advice, Poor weather forecast warning
- Where
- United Kingdom
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Smoking Cessation, Harm Reduction
Assisting Smokers to Switch to an e-Cigarette by Accelerating Learning of Adaptive Habits Using D-cycloserine
This study will evaluate the effects of a reward devaluation strategy, which has been researched in the past, combined/augmented with the medication d-cycloserine in assisting smokers to switch from combustible cigarette (CC) to…
- Trial name
- NCT05994703
- Testing
- d-cycloserine, Juul e-cigarette
- Where
- 2 sites in United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Rose Research Center, LLC
Smoking, Tobacco Smoking
CSD1601: A Study to Evaluate the Exposure to Tar and Nicotine From Two Cigarette Products That Contain a Menthol Capsule in the Filter
This study will evaluate exposure to tar and nicotine from two cigarette products that contain a menthol capsule in the filter, and provide a basis for comparing mouth-level exposure when smokers smoke the two cigarette products.
- Conditions
- Smoking, Tobacco Smoking, Tobacco Use
- Trial name
- NCT04529551
- Testing
- 1601A, 1601B
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- RAI Services Company
Substance Dependence
Relapse Prevention Study in Newly Abstinent Smokers
The purpose of this study is to determine the effect of GSK598809 as compared to placebo in preventing recently-quit smokers from going back to smoking.
- Trial name
- NCT00793468
- Testing
- GSK598809, Nicotine Replacement Transdermal Patch
- Where
- 10 sites in United States
- Sponsor
- GlaxoSmithKline
Electronic Cigarette Use
Study to Characterize Puffing Topography With Use of JUUL Electronic Nicotine Delivery Systems (ENDS) in Adult, Closed-System ENDS Consumers
A randomized, open label, 2-group, 4-period cross-over study in adult closed system ENDS consumers designed to evaluate puff topography parameters with use of JUUL ENDS products (Virginia Tobacco, Menthol, Mint, and Mango…
- Trial name
- NCT04088175
- Testing
- JUUL ENDS - Virginia Tobacco 5% nicotine strength, JUUL ENDS - Virginia Tobacco 3% nicotine strength, JUUL ENDS - Menthol 5% nicotine strength
- Where
- 2 sites in United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Juul Labs, Inc.
Smoking Cessation
Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date
The hypothesis is that varenicline will be effective (compared with placebo) for smoking cessation when subjects are allowed to set their own quit date within the first 5 weeks of treatment.
- Trial name
- NCT00691483
- Testing
- varenicline
- Where
- 33 sites in United States, Argentina and 12 more
- Volunteers
- 659 people
- Sponsor
- Pfizer